13D Filings
Trinity Biotech plc
TRIB
Amendment
Ownership

17.00%

Total Shares

69,450,720

Issuer CIK

888721

CUSIP

896438504

Event Date

Dec 1, 2025

Accepted

Dec 4, 2025, 08:27 PM

Reporting Persons (3)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
MiCo IVD Holdings, LLC
Other
17.00%69,450,720069,450,720
AI n M net Ltd.
Other
17.00%69,450,720069,450,720
Wonyong Park
Individual
17.00%69,450,72069,450,7200
Disclosure Items (6)

Security Title

Class 'A' Ordinary Shares

Issuer Name

Trinity Biotech plc

Issuer Address

IDA Business Park, County Wicklow, L2, A98 H5C8

Filing Persons

Item 2(a) of the Schedule 13D is hereby amended and restated in full as follows: This Amendment No. 5 is being filed jointly by MiCo IVD, AI n M net Ltd., a limited company incorporated in South Korea ("AI n M") and Wonyong Park (collectively, the "Reporting Persons"). Following completion of the 2025 MiCo IVD Purchase, AI n M beneficially owns all of the equity interests in MiCo IVD. Mr. Park serves as the manager, chief executive officer and president of MiCo IVD. Certain information regarding each director and executive officer of AI n M is set forth on Annex B filed herewith.

Business Address

Item 2(b) of the Schedule 13D is hereby amended and restated in full as follows: The address of AI n M is 8F, 27 Hwangsaeul-ro 360beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea. The address of MiCo IVD is 85 Orchard Road, Skillman, New Jersey 08558. The address of Mr. Park is 15F Aju B/D, 679-5 Yeoksam-dong, Gangnam-gu, Seoul, Republic of Korea.

Principal Occupation

Item 2(c) of the Schedule 13D is hereby amended and restated in full as follows: The principal business of AI n M is wholesale and retail trade. The principal business of MiCo IVD is investing in securities of the Issuer. The principal occupation of Mr. Park is investment associate.

Convictions

Item 2(e) of the Schedule 13D is hereby amended and restated in full as follows: During the last five years, none the Reporting Persons, nor any person identified in Item 2(a), has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Citizenship

Item 2(f) of the Schedule 13D is hereby amended and restated in full as follows: AI n M was formed in South Korea. MiCo IVD was formed in Delaware, United States. Mr. Park is a citizen of South Korea.

Item 3 of Schedule 13D is hereby amended to add the following: In connection with the 2025 MiCo IVD Purchase (as defined below), AI n M paid to DAYLI Holdings a total of 5,000,000,000 South Korean won from its working capital.

Item 4 of Schedule 13D is hereby amended by deleting the final two paragraphs and replacing them with the following new paragraphs: On December 2, 2025, DAYLI Holdings, the beneficial owner of 100% of the interests of MiCo IVD, entered into a Share Purchase Agreement with AI n M (the "2025 Share Purchase Agreement"), pursuant to which DAYLI Holdings agreed to sell to AI n M all of its equity interests in MiCo IVD for a total of 5,000,000,000 South Korean won (the "2025 MiCo IVD Purchase"). The 2025 MiCo IVD Purchase closed on December 2, 2025, following which time AI n M became the sole shareholder of MiCo IVD. The foregoing description of the 2025 Share Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, an unofficial English translation copy of which is incorporated by reference as an exhibit to this Schedule 13D. The applicable Reporting Persons made all acquisitions as described herein for investment purposes. As of the date of this Schedule 13D, the Reporting Persons may determine to dispose of all or a portion of MiCo IVD's holdings in the Issuer. Any disposition of these holdings may be made through private or public sales, including pursuant to the Resale Registration Statement, any trading plans that MiCo IVD might adopt pursuant to Rule 10b-5(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any hedging transactions. The Reporting Persons intend to review their investment in the Issuer on an ongoing basis and, in the course of their review, subject to the Conversion Limitation (as defined above and if applicable), may acquire additional equity interests, may retain or sell all or a portion of the equity interests of the Issuer held by the Reporting Persons, may distribute such equity interests held by the Reporting Persons to other entities and/or may take actions (including through their affiliates) with respect to their investment or the Issuer, including, without limitation, communicating with the Issuer's board of directors (the "Board"), members of management or other security holders of the Issuer, or other third parties (including, among others, creditors) from time to time, taking steps to implement a course of action with respect to the Issuer, including, without limitation, engaging advisors, including legal, financial, regulatory, technical and/or industry advisors, to assist in any review, and evaluating strategic alternatives regarding the Issuer and the ADS Investment. Such discussions and other actions may relate to, subject to the terms and conditions of the documents described herein to which the Reporting Persons are a party, various alternative courses of action, including, without limitation, those related to an extraordinary corporate transaction (including, but not limited to, an acquisition, merger, business combination, reorganization or liquidation) involving the Issuer or any of its subsidiaries; a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; material asset purchases; the formation of joint ventures with the Issuer or any of its subsidiaries or the entry into other material projects; changes in the present business, operations, strategy, future plans or prospects of the Issuer, financial or governance matters; changes to the Board (including board composition) or management of the Issuer; nominating individuals for consideration by the nomination committee of the Board for appointment to the Board; changes to the capitalization, ownership structure, dividend policy, business or corporate structure or governance documents of the Issuer; de-listing or de-registration of the Issuer's securities, or any action similar to those enumerated above. The Reporting Persons reserve the right to, and may in the future, discuss, meet with, and/or send correspondence to (a) the Issuer's management and/or Board, (b) other holders of securities of the Issuer, and/or (c) other third parties (including creditors) to discuss and/or formulate any plans or proposals regarding the Issuer or its securities. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. There can be no assurance, however, that any of the Reporting Persons will take any of the foregoing actions, and the Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or plans or proposals with respect thereto. This document (including the foregoing statements in this paragraph) is not intended to, and does not, constitute or form part of any offer, possible offer, invitation or the solicitation of an offer by the Reporting Persons to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to this document or otherwise. The information set forth in or incorporated by reference in Item 3 of this Schedule 13D is incorporated by reference into this Item 4.

Percentage of Class

Item 5(a) of the Schedule 13D is hereby amended and restated in full as follows: The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference. As of the date hereof, the Reporting Persons may be deemed to beneficially own 69,450,720 Ordinary Shares consisting of: (i) 2,237,969 ADSs, which represent 44,759,380 Ordinary Shares and (ii) 1,234,567 ADSs representing 24,691,340 Ordinary Shares issuable upon conversion of the Convertible Note. This represents an aggregate beneficial ownership of 17.0% of the Ordinary Shares, calculated on an as-converted basis assuming full conversion of the Convertible Note into ADSs. The percentage of beneficial ownership is based upon 383,881,600 Ordinary Shares reported to be outstanding by the Issuer as of March 15, 2025 in the Issuer's final prospectus filed pursuant to Rule 424(b)(3) on March 31, 2025 and the 24,691,340 Ordinary Shares represented by ADSs issuable upon conversion of the Convertible Note held by MiCo IVD. AI n M may be deemed to be the beneficial owner of the Ordinary Shares beneficially owned by MiCo IVD through its ownership interests in MiCo IVD. Mr. Park may be deemed to be the beneficial owner of the Ordinary Shares beneficially owned by MiCo IVD through his position as manager, chief executive officer and president of MiCo IVD. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that AI n M or Mr. Park is the beneficial owner of Ordinary Shares referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and AI n M and Mr. Park expressly disclaim beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.

Number of Shares

Item 5(b) of the Schedule 13D is hereby amended and restated in full as follows: The aggregate number and percentage of the Ordinary Shares beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.

Transactions

Item 5(c) of the Schedule 13D is hereby amended and restated in full as follows: Except as set forth in this Schedule 13D, none of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any other person named in Item 2, has engaged in any transaction in Ordinary Shares during the past 60 days.

Item 7 of Schedule 13D is hereby amended to add the following: Exhibit Annex B Exhibit No. 18 English Translation of Share Purchase Agreement, dated December 2, 2025, by and between DAYLI Holdings and AI n M. Exhibit No. 19 Joint Filing Agreement dated December 4, 2025, by and among the Reporting Persons. Except as expressly modified hereby, all provisions of the Schedule 13D shall continue in full force and effect.

Trinity Biotech plc — Schedule 13D | 13D Filings